| Abstrakt: |
The article discusses a clinical trial, NCT06636123, focusing on the use of GZ17-6.02 to delay progression of castration-resistant prostate cancer. The trial aims to assess radiographic progression-free survival, biochemical response rate, duration of response, objective response rate, radiographic response duration, overall survival, safety, and tolerability of GZ17-6.02. The study involves men with advanced castration-resistant prostate cancer who have previously received androgen deprivation therapy and an androgen receptor pathway inhibitor. [Extracted from the article] |
